Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant bevacizumab plus gemcitabine/cisplatin versus chemotherapy alone for stage IIIA non-small cell lung cancer
ChiCTR-ONRC-12002397Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate. Started Jun 2012; status: recruiting.
02
Drugs
bevacizumabgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002397.